Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million Presented positive interim Phase 1/2 data from GTX-102 Angelman syndrome study demonstrating that Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains consistent with or exceeding D...
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Conference Call Informat...
RALEIGH, N.C.--(BUSINESS WIRE)-- Advance Auto Parts (NYSE: AAP), a leading automotive aftermarket parts provider, the official auto parts retailer of NASCAR, and official partners of the NTT INDYCAR SERIES and Indianapolis Motor Speedway, is kicking off the summer travel season by offering its Speed Perks loyalty rewards members the chance to win a bucket-list motorsports experience to “Do the Double.” This press release features multimedia. View the full release here: On May 26, Advance will send one winner and their guest on a free VIP experience to attend the 108th running of the famed In...
FRANKLIN, Tenn.--(BUSINESS WIRE)-- Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights Revenue totaled $768.1 million, an increase of 9.1% over the first quarter of 2023 Same facility revenue increased 9.2% compared with the first quarter of 2023, including an increase in revenue per patient day of 6.9% and an increase in patient days of 2.2% Net income attributable to Acadia totaled $76.4 million, or $0.83 per diluted share Adjusted income attributable to Acadia totaled $77.3 millio...
A director at Caterpillar Inc sold 12,881 shares at 349.214USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Archrock Reports First Quarter 2024 Results HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock”,” the “Company,” “we,” “us,” “our”) today reported results for the first quarter 2024. First Quarter 2024 Highlights Revenue for the first quarter of 2024 was $268.5 million compared to $229.8 million in the first quarter of 2023.Net income for the first quarter of 2024 was $40.5 million compared to $16.5 million in the first quarter of 2023.Adjusted EBITDA (a non-GAAP measure defined below) for the first quarter of 2024 was $131.0 million compared to $97.2 mil...
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with. “In rare disease, corporate responsibility means pushing for progress and change t...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025 WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 stu...
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI). The pivotal Phase 3 portion of the Orbit study has randomized 158 patients ages 5 to 25 years, and the Cosmic study has completed enroll...
Archrock Announces Quarterly Cash Dividend and Extends Share Repurchase Authorization HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today announced that its Board of Directors has declared a quarterly dividend of $0.165 per share of common stock, or $0.66 per share on an annualized basis. The first quarter 2024 dividend will be paid on May 14, 2024 to all stockholders of record on May 7, 2024. The first quarter 2024 dividend per share amount is consistent with Archrock’s fourth quarter 2023 dividend and represents a year-over-year...
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024. The live and replayed webcast of the call will be available through ...
HOUSTON--(BUSINESS WIRE)-- Oceaneering International, Inc. ("Oceaneering") (NYSE:OII) today reported net income of $15.1 million, or $0.15 per share, on revenue of $599 million for the three months ended March 31, 2024. Adjusted net income was $13.9 million, or $0.14 per share, reflecting the positive impact of $(2.2) million in foreign exchange gains, and the associated $0.8 million of tax effects, along with $0.2 million of expenses related to discrete tax adjustments. Summary of Results (in thousands, except per share amounts) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.